LCTX vs ORGO
LCTX: Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships with major pharmaceutical companies. ORGO: Organogenesis is a tissue-engineered wound care and surgical reconstruction company whose financial health depends critically on Medicare reimbursement rates and FDA regulatory compliance.
Side-by-side fundamentals
| Metric | LCTX | ORGO | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $1.03 | $2.37 | |
| Market cap as of 2026-08-03 | $269M | $305M | |
| PEG as of 2026-08-03 | -0.01 | -2.40 | ORGO lower |
| Net margin as of 2026-08-03 | -431.2% | +0.5% | ORGO higher |
| Gross margin as of 2026-08-03 | +94.1% | +72.9% | LCTX higher |
| Operating margin as of 2026-08-03 | -256.5% | +0.5% | ORGO higher |
| ROE as of 2026-08-03 | -151.3% | +0.7% | ORGO higher |
| ROA as of 2026-08-03 | -63.3% | +0.5% | ORGO higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.03 | LCTX lower |
| Revenue growth (YoY) as of 2026-08-03 | -37.1% | +12.2% | ORGO higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +7.8% | ORGO higher |
| Beta as of 2026-08-03 | 1.51 | 1.66 | |
| 1-year return as of 2026-07-27 close | -8.8% | -48.7% | LCTX higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.